P3 Health Partners Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
P3 Health Partners Inc (PIII) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...
10-Q: Quarterly report
P3 Health Partners to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
P3 Health Partners Inc.'s (NASDAQ:PIII) Path To Profitability
P3 Health Partners Reaffirms Guidance for 2023 and Announces Guidance for 2024
P3 Health Partners Inc. (NASDAQ:PIIIW) Short Interest Down 24.7% in January
P3 Health Partners Inc. (NASDAQ:PIIIW – Get Rating) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 17,40
P3 Health Partners Inc. (NASDAQ:PIIIW) Sees Significant Increase in Short Interest
P3 Health Partners Inc. (NASDAQ:PIIIW – Get Rating) saw a significant increase in short interest in the month of December. As of December 30th, there was short interest totalling 15,800 shares, an i
P3 Health Partners Announces Select Preliminary Fourth Quarter and Full Year 2021 Results, and Introduces 2022 Outlook
Strong revenue growth of 46% for the fourth quarter and 32% for full year 2021 Full year 2022 revenue expected to be up to $1 billion, a 56% increase vs. prior year At-risk Medicare Advantage members
P3 Health Partners to Participate at Upcoming Investor Conferences
HENDERSON, Nev., March 07, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners, Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today
No Data